ProCE Banner Activity

Key Considerations in Selecting Second-line Therapy for Patients With CLL/SLL

Clinical Thought

Read this expert commentary on key factors that should be considered when recommending second-line and beyond therapy for previously treated patients with CLL/SLL.

Released: May 15, 2024

Expiration: May 14, 2025

Share

Faculty

Nicole Lamanna

Nicole Lamanna, MD

Judy Horrigan Professor of Medicine, Leukemia Service
Director of the Chronic Lymphocytic Leukemia Program
Hematologic Malignancies Section
Herbert Irving Comprehensive Cancer Center
NewYork-Presbyterian/Columbia University Medical Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC in partnership with CLL Society.

ProCE Banner

Supporters

Supported by educational grants from AbbVie Inc.; AstraZeneca; Beigene, Ltd.; and Bristol Myers Squibb.

AbbVie Inc.

AstraZeneca

BeiGene, Ltd.

Bristol Myers Squibb

Partners

CLL Society

ProCE Banner

Faculty Disclosure

Primary Author

Nicole Lamanna, MD

Judy Horrigan Professor of Medicine, Leukemia Service
Director of the Chronic Lymphocytic Leukemia Program
Hematologic Malignancies Section
Herbert Irving Comprehensive Cancer Center
NewYork-Presbyterian/Columbia University Medical Center
New York, New York

Nicole Lamanna, MD: consultant/advisor/speaker: AbbVie, Adaptive Biosciences, Allogene Therapeutics, AstraZeneca, BeiGene, Genentech, Genmab, Lilly/Loxo, Pharmacyclis/Janssen; researcher (paid to institution): AbbVie, AstraZeneca, BeiGene, Genentech, Genmab, Loxo/Lilly, MingSight, Octapharma, Oncternal.